Waystar (WAY) Q4 2025 earnings review
Iodine Acquisition Fuels Revenue Acceleration; Margins Expand
Waystar closed FY25 with a significant acceleration in top-line growth, reporting 24% YoY revenue increase to $303.5M, largely driven by the successful integration of Iodine Software. This marks a sharp pivot from the ~12-15% organic growth range seen in prior quarters. Crucially, the acquisition did not dilute profitability; Adjusted EBITDA margins expanded to 43% (up from 41% a year ago). While GAAP Net Income remained flat YoY ($20M) due to acquisition-related costs and higher interest expense, the underlying business demonstrated leverage. Management issued bullish FY26 guidance projecting ~17% growth at the midpoint, signaling confidence in the combined platform's cross-sell potential.
🐂 Bull Case
The Iodine Software acquisition is performing ahead of plan. Subscription revenue surged 38% YoY to $167.8M, significantly outpacing the corporate average. This mix shift towards recurring subscription revenue enhances visibility and quality of earnings.
Typically, large integrations pressure margins. Waystar bucked this trend, delivering a 43% Adjusted EBITDA margin in Q4 (up from 40-42% in recent quarters), proving the scalability of their automated revenue cycle platform.
🐻 Bear Case
Interest expense rose to $21.9M in Q4 (vs $19.0M YoY), and net debt stands at ~$1.4B following the acquisition. While leverage is managed, the increased debt service burden dampens GAAP net income growth.
While subscription revenue soared, volume-based revenue grew only 11% YoY ($134.2M). This segment remains sensitive to patient utilization trends, which showed signs of reverting to historical norms in Q3.
⚖️ Verdict: 🟢🟢
Bullish. Waystar executed a major acquisition while expanding margins—a rare feat in software M&A. The accelerated growth profile and robust FY26 guidance outweigh concerns over temporary GAAP earnings suppression from deal costs.
Key Themes
Subscription Revenue Surge
The revenue mix is shifting favorably. Subscription revenue grew 38% YoY to $167.8M, driven by the Iodine contribution and core organic strength. This segment now significantly outweighs volume-based revenue ($134.2M), improving predictability. This divergence is the widest it has been in FY25.
Enterprise Traction
Waystar continues to move upmarket successfully. The count of clients contributing >$100k LTM revenue grew 16% YoY to 1,391. With Net Revenue Retention (NRR) at 112%, the 'land and expand' strategy is working, particularly as the Iodine cross-sell opportunity begins.
Acquisition & Integration Costs
GAAP profitability took a hit from deal mechanics. Q4 included $14.9M in acquisition and integration costs (up from just $0.2M in Q3). While Adjusted EBITDA adds this back, these are real cash outflows that suppressed GAAP Net Income to $20M (flat YoY) despite a $60M jump in revenue.
AI Platform Narrative
Management is heavily leaning into the 'AI-powered' narrative, citing 'autonomous revenue cycle' capabilities. The integration of Iodine's clinical AI with Waystar's financial data is central to the thesis, though specific monetary breakout of AI-only SKUs remains opaque.
Leverage Profile
Net debt increased to ~$1.4B to fund the Iodine transaction. Interest expense is now running at ~$88M annualized run-rate (based on Q4's $21.9M). While cash flow is strong ($67M CFO in Q4), deleveraging will be a key metric to watch in FY26.
Other KPIs
Accelerating. Up 29% YoY. The margin expansion to 42.5% (vs 41.0% last year) demonstrates that the company is capturing synergies quickly or that the acquired Iodine business has a superior margin profile.
Stable. Represents a healthy conversion from Adjusted EBITDA (~62%). FY25 total Unlevered FCF was $365M, supporting the company's ability to service its increased debt load.
Stable. Down slightly from 113% in Q3 and 115% in Q2 (which were boosted by competitor outage effects), but remains well above the 110% historical baseline, indicating sticky relationships.
Guidance
Accelerating. The midpoint ($1.284B) implies ~17% YoY growth over FY25's $1.099B. This confirms the new growth baseline established in Q4 is expected to persist through the full year.
Accelerating. Implies ~16% growth at the midpoint. The implied margin is ~41.6%, slightly lower than Q4's 42.5%, potentially suggesting some conservative buffer or continued integration spend.
Accelerating. Midpoint ($326M) represents substantial growth (+24%) over FY25's $263M, outpacing revenue growth. This suggests efficiency gains below the operating line or tax benefits.
Key Questions
Volume-Based Revenue Deceleration
Volume-based revenue growth slowed to 11% in Q4 compared to 14-15% in H1. Is this purely a reversion of patient utilization to historical means, or are there competitive pressures in the payments segment?
Organic vs. Inorganic Growth in FY26
With FY26 guidance set at ~17% growth, how much of this is the annualized contribution of Iodine versus core organic growth? Are we returning to the 10-12% organic growth rate seen in Q3?
Integration Costs Runway
Acquisition costs spiked to nearly $15M in Q4. How should we model these one-time costs fading throughout FY26 to get a clearer picture of GAAP profitability?
Cross-Sell Velocity
Management noted low client overlap with Iodine in previous calls. Have you closed any joint platform deals in Q4, and what is the assumed contribution of cross-sell in the FY26 guidance?